ASCO Congratulates Stephen M. Hahn, MD, FASTRO, on Confirmation as FDA Commissioner

Statement by Howard A. "Skip" Burris III, MD, FACP, FASCO
For immediate release
December 12, 2019

Contact
Rachel Martin
(571) 483-1383
Rachel.Martin@asco.org

"The American Society of Clinical Oncology (ASCO) congratulates Stephen M. Hahn, MD, FASTRO, on his confirmation by the United States Senate to serve as the next Commissioner of the U.S. Food and Drug Administration (FDA).

"An oncologist with more than 30 years of experience providing direct patient care, Dr. Hahn understands how critical it is for Americans living with cancer to have access to innovative drugs and medical devices that safely and effectively diagnose, treat, manage, and cure their disease.

"ASCO has had a long and productive collaboration with the FDA in support of its important role in protecting public health by reducing cancer incidence and supporting innovations in treatment to improve the lives of individuals with cancer. We look forward to working with Dr. Hahn on initiatives to improve the drug development process, streamline and modernize clinical trials, harness big data to better learn from every patient, and to reduce and eliminate tobacco-related diseases, including cancer."

About ASCO:

Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to
making a world of difference in cancer care. As the world's leading organization of its kind, ASCO represents nearly 45,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of the highest-quality patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation. Learn more at www.ASCO.org, explore patient education resources at www.Cancer.Net, and follow us on Facebook, Twitter, LinkedIn, and YouTube.